您的当前位置:首页 > 行业数据 > POETYKPSO-LTE:2年期氘可来昔替尼用药安全性结果
图片属性
图片格式:PNG 图片大小:66KB 图片尺寸:1206*900
同报告图片
 / 4
POETYKPSO-LTE:2年期氘可来昔替尼用药安全性结果_第1页
5qC55o2u5Zu+54mH5Lit55qE5pWw5o2u77yM55Sf5oiQ55qE6KGo5qC85aaC5LiL77yaCgp8IOmhueebriAgICAgICAgIHwg5q+U5L6LICglKSB8CnwtLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tfAp8IFNBRSAgICAgICAgICB8IDkuNSAgICAgIHwKfCDlr7zoh7TlgZzoja8gQUUgIHwgNC41ICAgICAgfAp8IOatu+S6oSAgICAgICAgIHwgMC41ICAgICAgfAoK6LWE5paZ5p2l5rqQ77yaQnIgSiBEZXJtYXRvbC4gMjAyNDsxOTAoNSk6NjY4LTY3Oe+8jOWNjuazsOeglOeptg==
POETYKPSO-LTE:2年期氘可来昔替尼用药安全性结果_第2页
POETYKPSO-LTE:2年期氘可来昔替尼用药安全性结果_第3页
POETYKPSO-LTE:2年期氘可来昔替尼用药安全性结果_第4页
5qC55o2u5Zu+54mH5Lit55qE5pWw5o2u77yM5Lul5LiL5piv6KGo5qC877yaCgp8IOeWvueXheexu+WIqyAgICAgICAgICAgfCDmr5TkvosgKCUpIHwKfC0tLS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS18Cnwg5YW25LuW55a+55eFICAgICAgICAgICB8IDgxICAgICAgIHwKfCDogr/nmKQgICAgICAgICAgICAgICB8IDkgICAgICAgIHwKfCDkuK3mnqLnpZ7nu4/ns7vnu5/nlr7nl4UgICB8IDEwICAgICAgIHwKCui1hOaWmeadpea6kO+8mkdCRO+8jOWNjuazsOeglOeptg==
POETYKPSO-LTE:2年期氘可来昔替尼用药安全性结果_第5页
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
所属报告: 翰森制药-港股公司研究报告-创新蕴豪情龙头迎初昕-241229(111页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠